Neeta Pradhan, MSc

CRS:

BJMC

Role:

Laboratory

Position:

TB Laboratory Coordinator

Email:

neetapradhanpune@gmail.com

Neeta Pradhan is TB Laboratory Coordinator at the BJGMC-CRS in Pune, India. She has worked as Laboratory Manager at Golwilkar Metropolis Health Services where she was responsible for technical and quality aspects of laboratory testing.

She worked as a Laboratory Coordinator at NARI (National AIDS Research Institute) Clinical Trial Unit for various NIH-funded clinical stuies in the HIV Prevention Trials Network (HPTN), the AIDS Clinical Trial Group (ACTG), and the Microbicide Trial Network (MTN). She was responsible for lab quality management, administration, monitoring and supervision, and coordination and communication as well as additional institutional responsibilities such as lab accreditation.

She has also handled CONDRAD (ICMR) project in the capacity of a Laboratory Coordinator at NARI. She is a NABL (National Accreditation Board for Testing & Calibration of laboratory) 15189 trained internal auditor as well as being trained at GCLP by PPD.

She completed her post graduation at BJGMC, which is affiliated with the University of Pune.

  • Voting Member, Laboratory Technologist Committee (Dec 2017-Nov 2019)
  • Member, TB Laboratory Core Team

Categories

Leadership Committees
CRS
Roles

Clinical Trials

P1078: A Phase IV Randomized Double-Blind Placebo-Controlled...

P1078 is a Phase IV, randomized, double-blind, placebo-controlled study of HIV-infected pregnant women and the infants born to...

Read More

A5290, A Randomized, Phase 2b Study of a Double-Dose...

Rifampin (RIF), the cornerstone of TB treatment, has very problematic drug-drug interactions with PIs. The use of relatively...

Read More

A5332: Randomized Trial to Prevent Vascular Events in HIV...

REPRIEVE (A5332) is a large double-blind, randomized, placebo-controlled study of pitavastatin or placebo for about 72 months....

Read More

A5253: Sensitivity and Specificity of Mycobacterium...

An estimated 3 million HIV-infected individuals will enter programs for antiretroviral (ARV) treatment in the coming year, with...

Read More

A5300B/I2003B/PHOENIX, Protecting Households On Exposure to...

This study will compare the efficacy and safety of 26 weeks of delamanid (DLM) versus 26 weeks of isoniazid (INH) for preventing...

Read More